Dapagliflozin (Forxiga®)

Assessment Status Rapid review complete
Drug Dapagliflozin
Brand Forxiga®
Indication Indicated in adults aged 18 years and older with Type 2 Diabetes Mellitus to improve glycaemic control as: Monotherapy: When diet and exercise alone do not provide adequate glycaemic control in patients for whom use of metformin is considered inappropriate due to intolerance. Add-on combination therapy: In combination with other glucose lowering drugs including insulin, when these, together with diet and exercise, do not provide adequate glycaemic control.
Assessment Process
Rapid review commissioned 10/10/2012
Rapid review completed 22/10/2012
Rapid review outcome Full Pharmacoeconomic Evaluation Recommended
Full submission received from Applicant 01/08/2013
NCPE assessment completed 31/12/2013
NCPE assessment outcome Reimbursement not recommended at this time

Technical Summary

December 2015

The HSE has approved reimbursement following confidential price negotiations.